Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Forecast Target, Generating 33.9% Profit

May 30, 2024
ELI LILLY AND COMPANY (LLY) investors saw substantial gains as the stock hit the forecast price target set by QuantWave, resulting in a profit of 33.9%. The forecast, issued on November 14, 2023, signaled a long position with a price of 603.25 $. On May 30, 2024, the stock reached the target price of 807.75 $, validating QuantWave's prediction.

This achievement highlights the accuracy and value of QuantWave's analytics in guiding investors towards profitable opportunities. The successful forecast for ELI LILLY AND COMPANY reflects the platform's ability to provide reliable insights into market trends and stock movements.

Several factors may have contributed to LLY's price movement, including positive developments in its product pipeline, financial performance, and overall market conditions within the pharmaceutical industry. Investors who acted on the forecast had the opportunity to capitalize on this uptrend and secure significant returns.

QuantWave continues to offer a wide range of stock forecasts, providing users with potential opportunities for profit. By utilizing the platform's automated forecasting capabilities, investors can make informed decisions and optimize their investment strategies. Additionally, individuals interested in exploring QuantWave's investment strategy further can benefit from QuantSchool's educational resources, which offer comprehensive insights into generating consistent income using the platform's forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 8, 2025ELI LILLY AND COMPANY Hits Price Target Forecast with 18.31% Profit - QuantWave Achieves Success Once Again  ~2 min.

ELI LILLY AND COMPANY, one of the leading pharmaceutical companies, recently saw its stock price hitting the forecasted target with a profit of 18.31% as predicted by QuantWave on June 4, 2025....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Forecast as QuantWave Users Gain 17.38% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved the price target forecast set by QuantWave, marking a significant success for users of the automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Target Forecast with 17.25% Profit: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a leading pharmaceutical company, recently saw its stock hit the target forecast set by QuantWave, yielding a profit of 17.25%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Profit of 23.55%: A Success Story for QuantWave  ~2 min.

ELI LILLY AND COMPANY, a prominent player in the pharmaceutical industry, recently achieved a significant milestone by hitting a price target forecast generated by the innovative forecasting platform, QuantWave. The forecast, which indicated a short direction signal on April 17, 2025, at a price of 836.4 USD, proved to be accurate as the stock reached the predicted target price of 639.46 USD on Au...


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Target Forecast with 22.13% Profit  ~1 min.

ELI LILLY AND COMPANY stock successfully reached the forecasted target price of 639.46 $ on August 7, 2025, resulting in a profit of 22.13% for investors....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


VRTXJanuary 2, 2025New Report Predicts Positive Future for Vertex Pharmaceuticals Inc.  ~2 min.

According to a recent report, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is expected to experience a surge in its stock value in the coming months....


NVOJuly 29, 2025NOVO NORDISK A/S Hits Price Target with 24.77% Profit: QuantWave Forecasts Success  ~2 min.

NOVO NORDISK A/S, a leading pharmaceutical company, recently achieved its price target forecast with a 24.77% profit, as predicted by QuantWave, an automated forecasting platform....


NVOMarch 4, 2024NOVO NORDISK A/S Hits Price Target Forecast on QuantWave with 34.42% Profit  ~1 min.

NOVO NORDISK A/S, a leading pharmaceutical company, has seen its stock price reach the forecasted target on QuantWave, yielding a profit of 34.42%....


REGNFebruary 26, 2025Regeneron Pharmaceuticals Faces Legal Pressure and Growth Potential, According to Analysts  ~2 min.

Regeneron Pharmaceuticals, Inc. (REGN) is currently facing mounting pressure on both its sales and legal fronts....